Sophie’s Choice for Oncologists: Who Gets New Life-Saving Drug
- First CAR-T therapy soon approved, but production roadblocks
- Some dying patients won’t get it in time: ‘God, it’s awful’
This article is for subscribers only.
It’s a choice no doctor ever wants to make: which patient will get a chance to live, and which will not.
That is a decision oncologists may soon confront when the first two products in a revolutionary new way to treat cancer reach the U.S. market this year.